Shionogi to acquire RADICAVA business from Tanabe Pharma America.

Shionogi, a discovery-based pharmaceutical company, agreed to acquire RADICAVA, a branded specialty pharmaceutical therapy used in the treatment of amyotrophic lateral sclerosis, from Tanabe Pharma America, a discovery-based pharmaceutical company. Financial terms are not disclosed. “We are pleased to welcome RADICAVA to Shionogi. This critically important medicine was created to reduce the devastating burden of ALS, and we are honored to assume responsibility for it and to sustain and grow the relationships Tanabe Pharma has established with the patient and healthcare communities in the US. We recognize the significant responsibility that comes with a widely utilized breakthrough medicine and will be conscientious stewards of this important drug," Isao Teshirogi, Shionogi CEO.